Peru: INS Issues Communications for Clinical Trials Impacted by COVID-19

Due to the COVID-19 outbreak, Peru’s National Institute of Health (Instituto Nacional de Salud (INS)) has issued the following communications:

- **Communique 003-2020-OGITT/INS**, regarding the current suspension of administrative procedures until further notice and the prioritization of COVID-19 research. (Google translation of Communique 003-2020-OGITT/INS)

- **Communique 002-2020-OGITT/INS**, which provides guidance for ongoing clinical trials regarding participant visits, recruitment, and access to trial treatment. (Google translation of Communique 002-2020-OGITT/INS)

- **Communique 001-2020-OGITT/INS**, which states that clinical trial initiation, maintenance and conclusion must continue under the responsibility of the sponsor, who may implement strategies to protect research participants. Any strategies implemented must be communicated to the INS by emailing consultaensayos@ins.gob.pe. (Google translation of Communique 001-2020-OGITT/INS)

Questions? Email us at NIAIDClinRegsSupport@mail.nih.gov.

Feedback? Take our 2-minute survey.

Follow us on Twitter.